Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.48 |
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | CASR | P41180 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | LDHA | P00338 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21066516 | 0.84 | ALDH1A1 (0.46) | RAB9AKMT2AMEN1L3MBTL1ALDH1A1 | |
| SCHEMBL22028845 | 0.82 | ALDH1A1 (0.50) | NPC1RAB9AKMT2AMEN1L3MBTL1 | |
| SCHEMBL1695235 | 0.77 | NPC1 (0.66) | NPC1RAB9AKMT2AMEN1EPHX2 | |
| SCHEMBL18076414 | 0.75 | KMT2A (0.55) | NPC1KMT2AMEN1 | |
| SCHEMBL21066510 | 0.74 | CNR2 (0.39) | EPHX2NR1H4HPGDSMN1; SMN2CASR | |
| SCHEMBL3357892 | 0.74 | CASR (0.54) | NPC1RAB9AKMT2AMEN1HPGD | |
| SCHEMBL21066552 | 0.74 | MASP2 (0.47) | KMT2AMEN1 | |
| SCHEMBL11729314 | 0.73 | NPC1 (0.50) | NPC1RAB9AKMT2AMEN1ALDH1A1 | |
| SCHEMBL7419905 | 0.72 | LDHA (0.50) | NPC1RAB9AKMT2AMEN1EPHX2 | |
| SCHEMBL29036587 | 0.72 | LDHA (0.50) | NPC1RAB9AKMT2AMEN1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4257192-A2 | ISOQUINOLINE DERIVATIVES AND THEIR USE FOR THE TREATEMTN OF OPHTHALMIC DISORDERS | Industrial Technology Research Institute (TW) | 2023-10-11 | — | — | EP | disclosed |
| EP-3505513-B1 | ISOQUINOLINE DERIVATIVES AND THEIR USE FOR THE TREATEMTN OF OPHTHALMIC DISORDERS | IND TECH RES INST (TW) | 2023-09-27 | — | — | EP | disclosed |
| US-10696638-B2 | Compounds for inhibiting AGC kinase and pharmaceutical compositions comprising the same | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2020-06-30 | — | — | US | disclosed |
| EP-3505513-A1 | ISOQUINOLINE DERIVATIVES AND THEIR USE FOR THE TREATEMTN OF OPHTHALMIC DISORDERS | Industrial Technology Research Institute (TW) | 2019-07-03 | — | — | EP | disclosed |
| US-20190194137-A1 | COMPOUNDS FOR INHIBITING AGC KINASE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194137-A1 | COMPOUNDS FOR INHIBITING AGC KINASE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | GRK4, NCOA4, GRK3 | NPC1 1605/4885RAB9A 4296/4885KMT2A 1680/4885 |
| US-10696638-B2 | Compounds for inhibiting AGC kinase and pharmaceutical compositions comprising the same | GRK4, NCOA4, GRK3 | NPC1 1605/4885RAB9A 4296/4885KMT2A 1680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.